This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017. For comparison, there were roughly 2,122 financing deals made last year. Continue to STAT+ to read the full story…
The company indicated that the investigation began in 2017 and picked up in intensity in late 2024 and early 2025. The SEC filing states that on Feb. Continue to STAT+ to read the full story…
billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 Continue to STAT+ to read the full story…
According to the New York Times, “Since 2017, tens of millions have been spent by the federal government on mass shooter training, and states have spent even more.”
In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.
These new additions join 12 other risk factors outlined by the commission, affiliated with University College London, in previous reports on dementia prevention, intervention, and care in 2017 and 2020.
Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022.
That was until 2017, when he founded a startup called Nucleai. For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images. Now, he’s scouring biopsy samples for cancer cells. Nucleai’s technology is not searching out signs of danger.
A new investigation, published on Friday in JAMA Network Open , confirmed the link to early deliveries at a massive scale, in a large cohort study capturing over half of the births that occurred in the United States between 1993 and 2017. Its results shed light on the way existing health inequities may be exacerbated by a worsening climate.
In 2017, at the age of 42, Susan Whitehead was diagnosed with an early form of breast cancer after discovering a lump in her breast. She embarked on a challenging path of treatment, including a recurrence with stage 2 cancer four years later. Susan underwent two lumpectomies, a mastectomy, radiation, and chemotherapy.
But the agency noted in a press release that it’s the largest year-over-year update for NIH-funded postdocs since 2017. The 8% pay bump is far short of the increase to $70,000 that was recommended by an NIH working group late last year.
Nye has previously spoken about the genetic disease, which makes it difficult for people with the condition to control their muscles and often leads to problems with walking and speech, in a documentary released in 2017. He said then that he didn’t have children because of concerns he would pass on the disease to them.
“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9 , which promised to cure numerous genetic diseases.
Abrams, a frequent commentator about vaping in the news media, including CBS This Morning, CNN, and The New Yorker, coordinated extensively with Juul on public messaging in 2017 and 2018, according to company emails.
She was seven months pregnant when the doctor brought it up in April 2017. She sat on the couch in the half-light, blinds shut against the heat. The whole thing made her feel less than, like some essential part of her had been removed. She shouldn’t eat before the operation.
In 2017, after receiving reports about the telehealth site, an investigator for the California medical board logged on to Lemonaid using an alias. Ho Anh had just started working at Lemonaid Health when he was caught up in a sting.
In 2017, he was elevated to CEO. Samarth “Sam” Kulkarni has been there from almost the beginning. The former McKinsey partner joined CRISPR Therapeutics in 2015 as its chief business officer. STAT spoke to Kulkarni about how the company reached this point, and where the field of CRISPR-based medicine is going.
Her mom, Kathy Cronin, lived her life in fear of the disease, an anxiety both her children and her doctors dismissed, until, in the summer of 2017, she developed symptoms that were impossible to ignore. It took her great-grandfather before she was born and her grandmother when she was 6 years old.
The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceutical company has spent on marketing to doctors since such data became available in 2017.
From 2017 to 2020, the company sold nearly 8,000 devices with the fake component. Under CEO Laura Perryman’s leadership, the company warped the design of their devices to earn more reimbursement money from insurers, resulting in unnecessary plastic parts that allowed doctors to claim around $18,000 more than they previously could.
years after accelerated approval for cancer drugs to be pulled from the market if follow-up trials didn’t show a benefit; by 2017, that timing dropped to 3.6 The study also found evidence that drugs granted accelerated approval, meant to be a temporary designation, are spending less time in limbo. In 2013, it took an average of 9.9
Laronde was founded by biotech creation firm Flagship Pioneering in 2017 to develop a new type of genetic medicine called endless RNA. RNA medicines startup Laronde is merging with another startup in the wake of a scientific misconduct issue that affected its leading drug candidates.
The employee, patient testing technician Qiqiuia Young, alleged in a 100-page lawsuit filed in 2017 that problems began when her co-workers at Stanford Cancer Center dressed as members of the Ku Klux Klan around Halloween.
By comparison, the FDA inspected 976 clinical study sites in 2017. In 2022, the health regulator inspected 537 hospitals and clinics that were conducting studies of medicines for which drug manufacturers were seeking approvals.
The company received the first FDA clearance for a standalone digital therapeutic in 2017 for reSET, a product that used cognitive behavioral therapy to treat substance use disorder. It was followed by clearances for reSET-O, an app for opioid use disorder, and Somryst, for insomnia.
My daughter, Mallory, died in 2017 at the age of 25 from a multiply resistant bacterial lung infection that followed a double-lung transplant necessitated by cystic fibrosis.
The kickback case began four years ago when the Department of Justice accused Teva of using the foundations to ensure that, from 2006 through 2017, Medicare patients did not have to make a copayment or deductible for the Copaxone multiple sclerosis drug. At the same time, Teva steadily raised the price of its drug by thousands of dollars.
are charged with knowingly selling defective lead testing machines between 2013 and 2017 that generated inaccurate results for tens of thousands of children across the country and for clients of at least one international relief organization, federal prosecutors said. Three former executives at Magellan Diagnostics Inc.
The first continuous glucose monitor was approved by the FDA in 2017. The sensor will pair with a smartphone app, which will provide blood glucose measurements every 15 minutes. Dexcom has not yet released the price of the device.
Although the first CAR-T was approved in 2017 for children, after it cleared malignancies in some on the brink of death, researchers hoping to use the tool in other pediatric cancers have struggled. The therapy eventually reached market as Breyanzi, one of three CAR-Ts approved for adult leukemia. The story was emblematic.
The initial effort to raise and sell chickens without using antibiotics began in 2017 as the company bet consumers would absorb the added expense. Continue to STAT+ to read the full story…
If the recent acceleration of new diagnoses persists, then 220,000 people younger than 20 would have type 2 diabetes in 2060, compared with 28,000 in 2017, the latest year for which data is available, according to projections published this month in Diabetes Care. The number of young people in the U.S.
” But based on a final regulation published Monday, Medicare is going against that public interest by giving a free pass to Medicare Advantage plans for any erroneous codes they submitted between 2011 and 2017. The amount of taxpayer money that insurers will get to keep because of that decision: $2 billion.
Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials.
Boger, 72, founded Vertex in 1989 and served in various roles until 2017. Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a proud parent.
Its trial was completed in 2017, but the company missed a deadline to seek a reporting extension. A rule went into effect in 2017 to strengthen reporting requirements. After receiving the FDA letter, Light Sciences posted results on Aug. 2, although outstanding issues remain with its submission.
In 2017, the Massachusetts state Legislature passed a law to ensure ease of access to birth control. It says there should be no copay for hormonal birth control prescriptions. It also allows women to fill a 12-month prescription at once. Infertility care has similar protections.
Smith was in STAT’s 2017 class of Wunderkinds , an annual selection of standout researchers who are launching their careers. Still, she knew from a very young age that she wanted to help people living with sickle cell disease. Now, as a research director at Vertex Pharmaceuticals, she is working on potential sickle cell medicines.
When I was diagnosed with breast cancer in 2017 and had bilateral mastectomies , I had more reconstruction options than my mother did. In 1983, I flew home from college to be with my mother as she woke up from a mastectomy. She opted out of breast reconstruction, choosing to “go flat” instead. Read the rest…
These practices, which occurred between 2009 and 2017, allegedly harmed the country and patients. At the same time, the agency is examining accusations that the drug company disseminated “defamatory claims and news” in hopes of influencing physicians and consumers to favor its own treatment over competing medicines.
From 2017 to 2020, the company implanted nearly 8,000 patients with these devices. Under her leadership, Stimwave warped the design of the device to better align with insurance codes, resulting in unnecessary plastic components that allowed the company to sell their products for thousands of dollars more than they otherwise could.
Overall estimated new infections dropped 12% in 2021 compared to 2017, according to data released Tuesday by the Centers for Disease Control and Prevention. The latest accounting of HIV incidence in the United States is a mixed bag. But the American South — which has had a longtime HIV problem compared with other areas across the U.S.
Case in point: Under the seemingly benign title, “Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval,” an article published recently in the Journal of the American Medical Association claims that among “cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did not improve (..)
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content